🇺🇸 FDA
Pipeline program

Pozelimab

R3918-AMD-2326

Phase 3 small_molecule active

Quick answer

Pozelimab for Age-related Macular Degeneration (AMD) is a Phase 3 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
REGENERON PHARMACEUTICALS, INC.
Indication
Age-related Macular Degeneration (AMD)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials